Predilife EBIT per Share
The EBIT per Share of Predilife (ALPRE.PA) as of Jul 26, 2026 is -1.06 EUR. In the previous year, EBIT per Share was -1.04 EUR — a change of 2.06% (lower).
Get this data via API
Financial Data API
EBIT per Share
-1.06EUR
YoY
2.06%
Last updated:
EBIT per Share of Predilife is 2026 -1.06 EUR. EBIT per Share of Predilife was 2025 -1.04 EUR. It decreases by 2.06% lower compared to the previous year.
Access this data via the Eulerpool API
Predilife Stock analysis
What does Predilife do? Predilife SA is a company specializing in predictive medicine. It was founded in Switzerland in 2011 and has since been based in Marseille, France. The company currently has around 50 employees, most of whom are scientists and doctors.
The idea for Predilife SA came from the realization that many diseases can be prevented if they are detected and treated in advance. As most diseases also have a genetic component, Predilife SA focuses on the development of tests that calculate individual disease risk based on individual genetics.
The business model of Predilife SA is based on the development and sale of predictive genetic tests for various diseases. The company works with health insurance companies, insurance companies, companies, as well as directly with end customers. The company believes that predictive tests represent an opportunity for many people to detect diseases early and take appropriate preventive measures.
The company offers predictive tests for a range of diseases, including cancer, cardiovascular diseases, neurodegenerative diseases, and diabetes. The tests are based on state-of-the-art molecular diagnostic methods that allow for the identification of genetic changes that increase individual disease risk. The tests are conducted in specialized laboratories and interpreted by qualified doctors and geneticists.
Predilife SA operates four different divisions and offers a range of predictive tests for each division:
Division 1: Cancer prevention
This division focuses on tests for common types of cancer such as breast, colon, and prostate cancer. The tests assess the individual risk of developing cancer and help optimize prevention and surveillance measures.
Division 2: Cardiovascular diseases
This division offers tests that assess the individual risk of cardiovascular diseases such as heart attack or stroke. The results are used to take targeted preventive measures.
Division 3: Neurological diseases
This division develops tests for neurodegenerative diseases such as Alzheimer's or Parkinson's. The results help determine individual risk and take appropriate preventive measures.
Division 4: Diabetes
This division offers tests that assess the individual risk of type 2 diabetes. The results are used to take targeted preventive measures.
In addition to predictive tests, Predilife SA operates its own research department that focuses on the development of new predictive tests and the further development of existing tests. The company collaborates with leading scientists and institutions worldwide.
Overall, Predilife SA aims to make predictive medicine accessible to as many people as possible. The company relies on state-of-the-art technologies and high professional competence. Predilife is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Predilife stock
EBIT per Share of Predilife is -1.06 EUR in 2026.
Access this data via the Eulerpool API
Income Statement — Predilife
All Key Metrics — Predilife
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth